APLS: A Closer Look at the Current Setup

APLS

This stock is worth a closer look at the current enterprise value/stock price.

Pros

→ 2 Approved early-stage drugs,

→ 7/28 PDUFA with solid data for next rare disease indication for EMPAVELI,

→ More attractive entry point for buying stock (~$2.25B MC and EV),

  ⚬ Valuation is now 1/2 where it was 6 months ago

→ ~$150M/quarter in product revenue with early products,

→ Early stage SiRNA asset to enhance effectiveness of SYFOVRE has exciting potential,

→ SYFOVRE safety issue seems rare and has not appeared in months,

→ CFO reiterated even before recent deal with Sobi for $250M up-front, that APLS has cash to profitability,

 ⚬ No more dilutions

Cons

→ Tough Q1 for revenue for lead drug - SYFOVRE,

  ⚬ $130M Q1 2025 vs. $168M in Q4 2024 and $137M Q1 2024;,

  ⚬ Main reason: funding shortages at co-pay assistance programs,

  ⚬ Likely resets base quarterly rev for future growth to $130M

→ Major competitor has similar drug and power of large-pharma marketing - Astellas,

→ SYFOVRE has serious safety issue, even if it is rare, and the positive effects of SYFOVRE are not readily apparent to pts,

→ Limited pipeline

 👉 Get full access to BPIQ Portfolios, hedge fund positions, and our detailed take on #APLS — upgrade to BPIQ Premium today!

Join BPIQ Elite & get...

• All catalyst & PDUFA dates!

• Big/Suspected Movers

• Hedge fund analysis & M&A data!

• Stock ideas from our model portfolios, which are beating XBI by a lot!  

---

This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.

Article history:

First published 7/9/25 EJV & AV